Innovent Biologics’ Mazdutide Outperforms Dulaglutide in Phase III T2D Study at EASD Meeting
Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings...
HKG: 1801
Innovent Biologics Presents Promising Phase I Data for IBI363 in Advanced NSCLC at WCLC
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has unveiled Phase...
Innovent Biologics’ Dupert Demonstrates Positive Results in Phase II NSCLC Trial
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Innovent Biologics’ IBI363 Earns FDA Fast-Track Designation for Advanced Melanoma Treatment
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has received fast-track...
Innovent Biologics Reports 46.3% YOY Revenue Growth and Expands Portfolio with New Approvals and NDAs
Innovent Biologics, Inc., a leading biopharmaceutical company based in China and listed on the Hong...
Innovent Biologics’ President Liu Yongjun Resigns, CEO De-Chao Micheal Yu Takes R&D Reins
Innovent Biologics Inc., a leading biopharmaceutical company based in China and listed on the Hong...
Innovent Biologics’ Fulzerasib Receives NMPA Approval for Advanced NSCLC Treatment in China
Innovent Biologics Inc., a biopharmaceutical company based in China and listed on the Hong Kong...
IASO Biotherapeutics’ CAR-T Therapy Fucaso Gets FDA Green Light for Lupus Treatment
IASO Biotherapeutics, a Chinese biotech firm, has received Investigational New Drug (IND) approval from the...
Innovent Biologics Reports Over RMB 2 Billion in Q2 2024 Sales, Highlighting 50% YOY Growth
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has reported a significant...
Innovent Biologics and Sanegene Bio Commence Phase I Clinical Trial for Hypertension siRNA Drug
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, in collaboration with...
Innovent Biologics’ Mazdutide NDA for Type 2 Diabetes Accepted for Review in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...
Innovent Biologics Partners with Wecomput Technology to Accelerate AI in Drug Development
Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has entered...
IASO Biotherapeutics’ CAR-T Therapy Fucaso Receives FDA IND Approval for Multiple Sclerosis
China-based IASO Biotherapeutics has announced that it has received Investigational New Drug (IND) approval from...
Innovent Biologics’ Mazdutide Achieves Primary and Secondary Endpoints in Phase III T2D Trial
Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has announced...
Suzhou Sanegene Bio Receives NMPA Approval for Clinical Trial of Antihypertensive siRNA Drug
Suzhou Sanegene Bio Inc., a leading RNAi specialist with research and development centers in both...
Ascentage Pharma’s Olverembatinib Receives Marketing Approval from Macau SAR for CML Treatment
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...
Innovent Biologics and IASO Biotherapeutics Amend Partnership, Focusing on CAR-T Therapy Fucaso
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced a...
Innovent Biologics Presents Positive Phase I Results for IBI343 at ESMO GI Congress 2024
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...
Innovent Biologics’ Mazdutide Shows Promise in Phase III Obesity Trial
Innovent Biologics Inc. (HKG: 1801), a biopharmaceutical company based in China, has announced the presentation...
Innovent Biologics’ IBI363 Shows Promising Results in Phase Ia/Ib Trial for Advanced Solid Tumors
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...